Literature DB >> 10204575

The SIV-infected rhesus monkey model for HIV-associated dementia and implications for neurological diseases.

D M Rausch1, E A Murray, L E Eiden.   

Abstract

The neuropathogenesis of human immunodeficiency virus (HIV)-associated dementia has remained elusive, despite identification of HIV as the causal agent. Although a number of contributing factors have been identified, the series of events that culminate in motor and cognitive impairments after HIV infection of the central nervous system (CNS) are still not known. Rhesus monkeys infected with simian immunodeficiency virus (SIV) manifest immunosuppression and CNS disease that is pathologically [L. R. Sharer et al. (1991) J. Med. Primatol. 20, 211-217] and behaviorally [E. A. Murray et al. (1992) Science 255, 1246-1249] similar to humans. The SIV model of HIV-associated dementia (HAD) is widely recognized as a highly relevant model in which to investigate neuropathogenesis. With better understanding of neuropathogenesis comes the opportunity to interrupt progression and to design better treatments for HAD. This becomes increasingly important as patients live longer yet still harbor HIV-infected cells in the CNS. The use of the SIV model has allowed the identification of neurochemical markers of neuropathogenesis important not only for HAD, but also for other inflammatory neurological diseases.

Entities:  

Mesh:

Year:  1999        PMID: 10204575     DOI: 10.1002/jlb.65.4.466

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  17 in total

Review 1.  In vitro and animal models of human immunodeficiency virus infection of the central nervous system.

Authors:  Chadd E Nesbit; Stanley A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

Review 2.  Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.

Authors:  Gloria Lee; Reina Bendayan
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

Review 3.  Biomarkers for neuroAIDS: the widening scope of metabolomics.

Authors:  Gurudutt Pendyala; Elizabeth J Want; William Webb; Gary Siuzdak; Howard S Fox
Journal:  J Neuroimmune Pharmacol       Date:  2006-10-10       Impact factor: 4.147

Review 4.  Cannabinoids as therapeutic agents for ablating neuroinflammatory disease.

Authors:  G A Cabral; L Griffin-Thomas
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-09       Impact factor: 2.895

5.  Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics.

Authors:  Thomas W North; Andradi Villalobos; Selwyn J Hurwitz; Jesse D Deere; Joanne Higgins; Payel Chatterjee; Sijia Tao; Robert C Kauffman; Paul A Luciw; James J Kohler; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

6.  Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules.

Authors:  J L Dzuris; J Sidney; H Horton; R Correa; D Carter; R W Chesnut; D I Watkins; A Sette
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 7.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

8.  Proteomic and metabolomic strategies to investigate HIV-associated neurocognitive disorders.

Authors:  Gurudutt Pendyala; Howard S Fox
Journal:  Genome Med       Date:  2010-03-30       Impact factor: 11.117

9.  Atypical nodular astrocytosis in simian immunodeficiency virus-infected rhesus macaques (Macaca mulatta).

Authors:  Keiko Y Petrosky; Heather L Knight; Susan V Westmoreland; Andrew D Miller
Journal:  J Med Primatol       Date:  2014-08-01       Impact factor: 0.667

10.  Expression of simian immunodeficiency virus (SIV) nef in astrocytes during acute and terminal infection and requirement of nef for optimal replication of neurovirulent SIV in vitro.

Authors:  Emily D Overholser; Gary D Coleman; Jennifer L Bennett; Rebecca J Casaday; M Christine Zink; Sheila A Barber; Janice E Clements
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.